- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT00933595
Longitudinal Studies of HIV-Associated Lung Infections and Complications (Lung HIV) (LHIV)
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
The Ohio State University Clinical Research Center (CRC), Patient Selection
Study Intervention Subjects:
365 HIV+ male and female smokers will be enrolled to the study and will be recruited over a two - four year period.
Inclusion criteria
- 18 years of age and older
- Diagnosis of HIV (Since the vast majority of our subjects will be recruited through the OSU Infectious disease clinics and HIV clinical research unit documentation of HIV status will not be a problem)
- Self-reported smoking (≥ 5 cigarettes per day to avoid inclusion of occasional, 'social' users and 'chippers');
- Able and willing to provide informed written consent.
Exclusion criteria:
- Inability to provide informed consent
- Inability to understand spoken English
- Currently diagnosed interstitial lung disease (i.e. sarcoidosis, idiopathic pulmonary fibrosis) or lung cancer.
Control Subjects Group A:
We will utilize normal subjects for the control study for the Diffusion Capacity of Lung for Carbon Monoxide (DLCO) and Diffusion capacity of Lung for Nitric Oxide (DLNO), recruited from the general population. We will recruit 5 males and 5 females in each decade of life from 21-30, 31-40, 41-50, 51-60, 61-70 (TOTAL= 50 subjects).
Inclusion criteria
- 21-70 years of age and older
- HIV Seronegative
- Able and willing to provide informed written consent.
Exclusion criteria:
- Inability to provide informed consent
- Inability to understand spoken English
- Current smoker or have smoked in the last 10 years or have a > 10 pack year history of smoking.
- Currently diagnosed interstitial lung disease (i.e. sarcoidosis, idiopathic pulmonary fibrosis) or lung cancer.
Control Subjects Group B:
We will utilize normal subjects for the control study for DLCO and DLNO, recruited from the general population. We will recruit 5 males and 5 females in each decade of life from 21-30, 31-40, 41-50, 51-60, 61-70 (TOTAL= 50 subjects).
Inclusion criteria
- 21-70 years of age and older
- HIV Seronegative
- Current or former smoker with at least a 5 pack year history of smoking
- Able and willing to provide informed written consent.
Exclusion criteria:
- Inability to provide informed consent
- Inability to understand spoken English
- Currently diagnosed interstitial lung disease (i.e. sarcoidosis, idiopathic pulmonary fibrosis) or lung cancer.
Typ studie
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
Ohio
-
Columbus, Ohio, Spojené státy, 43210
- Ohio State University
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria
Men and women at the AIDS Clinical Trials Unit(ACTU) will be eligible to participate if they meet four criteria: (a) 18 years of age and older; and (b) diagnosis of HIV; and (c) self-reported smoking on a daily basis; and (d) provide informed written consent.
Exclusion criteria
Persons who meet one or more of the following criteria will be excluded from the study: (a) persons with active psychosis or impaired mental status as judged by the clinic staff and confirmed with a Mini-Mental Status Exam); (b) unable to understand spoken English; (c) age less than 18 years.
Rationale: Persons with cognitive impairment may participate in the study if they are able to provide consent and answer questionnaire questions. No reason is identified to exclude persons with this characteristic. No special risks are posed to cognitively impaired persons who are able to provide consent. Persons who have active psychoses or impaired mental status as judged by the clinic staff and confirmed with a Mini-Mental Status Exam are not able to provide informed written consent and are unlikely to benefit from the treatment. These persons will be referred to appropriate mental health services and invited to participate when their mental status has improved.
Persons who are unable to understand spoken English would not be able to complete the assessments or benefit from the treatments. Less than 1% of the clinic population will be excluded on this basis. However, persons excluded from the study on this basis will be referred for standard smoking cessation treatment delivered in their native tongue. These community resources may be identified through the Ohio State University Nursing Center for Tobacco Intervention.
Younger adolescents (<18 years) will not be invited to participate in the study because we believe that they require treatments that are qualitatively different from those designed for older adolescents and adults. The treatments that will be evaluated in the proposed research are well suited to older adolescents and adults, but not developmentally tailored to younger adolescents. Less than 1% of the clinic population will be excluded on this basis. Most HIV+ children living in Columbus, Ohio receive HIV medical care through the F.A.C.E.S. outpatient clinic at Columbus Children's Hospital. Standard, age appropriate, smoking cessation treatment is available through the Health and Wellness Center at Columbus Children's Hospital. In the unlikely circumstance that a child <18 years of age wishes to participate in the proposed study, s/he will be referred to Health and Wellness Center at Children's Hospital for treatment or the Ohio State University Nursing Center for Tobacco Intervention for age appropriate smoking cessation community resources.
Pregnant women may not be included as subjects. While smoking during pregnancy is an important modifiable cause of poor pregnancy outcomes, little information is available on the safety or efficacy of varenicline. Therefore, participants who are pregnant will be excluded as subjects. Also, women who are breast-feeding will be excluded.
Other persons who are unable to use varenicline will be allowed to participate in the study but will not receive the varenicline component of treatment. A history and physical examination will be conducted as a component of the baseline evaluation.
People that have kidney problems or undergo kidney dialysis will not take the study drug, but will be given the option to take nicotine replacement therapy.
All persons excluded from the study will have the opportunity to receive smoking cessation treatment. We will provide referrals for treatment as clinically indicated.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Smoking Cessation
The overall smoking cessation rate for the intervention is 18.8 at 3 months, 13.1 at 6 months and 10.0 at 12 months.
|
A Motivational Interview session (~40-50 minutes) will be delivered by a trained nurse coordinator. Treatment with varenicline (1 mg daily during week 1 (pre-quit week) followed by 1 mg twice daily for weeks 2-12)or nicotine replacement therapy (21 mg of a skin patch + nicotine gum 4 mg ad lib added for breakthrough craving up to 20 pieces/day. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Časové okno |
|---|---|
|
To develop and evaluate a specialized smoking cessation intervention for the treatment of nicotine dependence in HIV-seropositive smokers.
Časové okno: 5 years
|
5 years
|
Sekundární výstupní opatření
Měření výsledku |
Časové okno |
|---|---|
|
To examine the effects of smoking cessation on the course of lung function decline, the prevalence of respiratory symptoms and the occurrence/progression of emphysema in a cohort of HIV-seropositive individuals.
Časové okno: 5 years
|
5 years
|
Spolupracovníci a vyšetřovatelé
Spolupracovníci
Vyšetřovatelé
- Ředitel studie: Hannah Peavy, MD, NHLBI Project Officer
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 652
- 3R01HL090331-05S1 (Grant/smlouva NIH USA)
Plán pro data jednotlivých účastníků (IPD)
Studijní data/dokumenty
-
Soubor dat jednotlivých účastníků
Identifikátor informace: LUNG-HIVKomentáře k informacím: NHLBI provides controlled access to IPD through BioLINCC. Access requires registration, evidence of local IRB approval or certification of exemption from IRB review, and completion of a data use agreement.
- Protokol studie
- Studijní formuláře
- Manuál postupů
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na HIV infekce
-
Ottawa Hospital Research InstitutePfizerDokončenoHIV infekce | HIV-1 infekce | Mycobacterium Avium Complex (MAC)Kanada
-
National Institute of Allergy and Infectious Diseases...DokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy
-
National Institute of Allergy and Infectious Diseases...AbbottDokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy
-
National Institute of Allergy and Infectious Diseases...DokončenoHIV infekce | Infekce Mycobacterium Avium-IntracellulareSpojené státy
-
National Institute of Allergy and Infectious Diseases...DokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy
-
National Institute of Allergy and Infectious Diseases...DokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy
-
National Institute of Allergy and Infectious Diseases...DokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy, Tanzanie
-
AbbottDokončenoHIV infekce | Intracelulární infekce Mycobacterium AviumSpojené státy, Portoriko
-
AbbottNational Cancer Institute (NCI)DokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy
-
Aaron Diamond AIDS Research CenterDokončenoHIV infekce | Infekce Mycobacterium Avium-Intracellulare | Tuberkulóza, infekce MycobacteriumSpojené státy
Klinické studie na Smoking Cessation
-
University of California, San FranciscoDokončeno
-
Duke UniversityNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH); Food and Drug Administration (FDA)UkončenoKouření cigaret | Odnětí nikotinuSpojené státy
-
University of OklahomaNational Institute on Drug Abuse (NIDA); Oklahoma State UniversityDokončenoZávislost na nikotinu | Kouření cigaret | Odnětí nikotinuSpojené státy
-
University of California, San FranciscoDokončeno
-
Queen Mary University of LondonPfizerDokončeno
-
H. Lee Moffitt Cancer Center and Research InstituteFlorida Biomedical Research Program - James & Esther KingNáborOdvykání kouření | Užívání alkoholuSpojené státy
-
University of MichiganNational Heart, Lung, and Blood Institute (NHLBI)DokončenoOdvykání kouření | Porucha užívání tabákuSpojené státy
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)Zatím nenabírámeKarcinom související s kouřením cigaretSpojené státy